Mesoblast (CHIA:MSB) - Stock Price, News & Analysis

MSB Stock Overview

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details

MSB fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 93.6% below our estimate of its fair value

Earnings are forecast to grow 61.47% per year

Risk Analysis

Shareholders have been diluted in the past year

Mesoblast Limited Competitors

Immutep

ASX:IMM

AU$465.5m

Clinuvel Pharmaceuticals

ASX:CUV

AU$680.3m

Dimerix

ASX:DXB

AU$192.2m

Imugene

ASX:IMU

AU$312.4m

Price History & Performance

Summary of all time highs, changes and price drops for Mesoblast
Historical stock prices
Current Share Price	AU$1.60
52 Week High	AU$1.83
52 Week Low	AU$0.26
Beta	2.34
11 Month Change	10.34%
3 Month Change	65.80%
1 Year Change	305.06%
33 Year Change	-5.88%
5 Year Change	-12.09%
Change since IPO	-66.35%

Recent updates

Shareholder Returns

	MSB	AU Biotechs	AU Market
7D	5.6%	-5.0%	1.4%
1Y	305.1%	9.8%	17.7%

Return vs Industry: MSB exceeded the Australian Biotechs industry which returned 9.9% over the past year.

Return vs Market: MSB exceeded the Australian Market which returned 16.9% over the past year.

Price Volatility

Is MSB's price volatile compared to industry and market?
MSB volatility
MSB Average Weekly Movement	9.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: MSB has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: MSB's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

Founded	Employees	CEO	Website
2004	73	Silviu Itescu	www.mesoblast.com

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

Mesoblast Limited Fundamentals Summary

How do Mesoblast's earnings and revenue compare to its market cap?
MSB fundamental statistics
Market cap	AU$1.83b
Earnings (TTM)	-AU$135.46m
Revenue (TTM)	AU$9.09m

201.5x

P/S Ratio

-13.5x

P/E Ratio

Is MSB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MSB income statement (TTM)
Revenue	US$5.90m
Cost of Revenue	US$41.07m
Gross Profit	-US$35.17m
Other Expenses	US$52.79m
Earnings	-US$87.96m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.077
Gross Margin	-595.87%
Net Profit Margin	-1,490.27%
Debt/Equity Ratio	23.8%

How did MSB perform over the long term?

See historical performance and comparison

MSB Stock Overview

Rewards

Risk Analysis

Mesoblast Limited Competitors

ASX:IMM

AU$465.5m

ASX:CUV

AU$680.3m

ASX:DXB

AU$192.2m

ASX:IMU

AU$312.4m

Price History & Performance

Recent News & Updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Forecast breakeven date pushed back to 2027

Full year 2024 earnings released: US$0.089 loss per share (vs US$0.11 loss in FY 2023)

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Forecast breakeven date pushed back to 2027

Full year 2024 earnings released: US$0.089 loss per share (vs US$0.11 loss in FY 2023)

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Independent Non-Executive Director recently bought AU$200k worth of stock

No longer forecast to breakeven

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

New minor risk - Share price stability

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

New major risk - Shareholder dilution

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

No longer forecast to breakeven

First half 2024 earnings released: US$0.038 loss per share (vs US$0.057 loss in 1H 2023)

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.14 loss in FY 2022)

New major risk - Share price stability

Forecast breakeven date pushed back to 2026

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Third quarter 2023 earnings released: US$0.025 loss per share (vs US$0.033 loss in 3Q 2022)

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.033 loss per share (vs US$0.04 loss in 2Q 2022)

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.035 loss in 1Q 2022)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Insider recently bought AU$111k worth of stock

Full year 2022 earnings released: US$0.14 loss per share (vs US$0.16 loss in FY 2021)

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Forecast to breakeven in 2025

Mesoblast Limited Provides Litigation Update

Third quarter 2022 earnings released: US$0.033 loss per share (vs US$0.044 loss in 3Q 2021)

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Forecast to breakeven in 2024

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

No longer forecast to breakeven

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Insufficient new directors

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Forecast to breakeven in 2024